17.10.2019 | Tracker

Game changing’ month as Erleada® and Rybelsus® approved by the FDA

By Nathan Cripps

Game changing' month as Erleada® and Rybelsus® approved by the FDA

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens.

During the month of September, there were over 140 submissions that were approved by the FDA. These approvals ranged from treatments for diabetes, prostate cancer, blood screening and AI technology advances amongst others. With these new treatments, screening options or technology advances gaining approval, 1,280 HCPs shared the news and their views online in 1,744 social media posts.

The most mentioned FDA approvals by healthcare professionals online

Brand nameCompound nameManufacturerBrand mentionsCompound mentionsTotal mentions
RybelsussemaglutideNovo Nordisk3682118
OfevnintedanibBoehringer Ingelheim123143
Nicotine PolacrilexanicotinePand L Dev LLC171734
KeytrudapembrolizumabMerck & Co61824
LenvimalenvatinibMerck & Co with Eisai41418
Buprenorphine HydrochlorideabuprenorphineActavis Elizabeth8816
Tramadol HydrochlorideatramadolSun Pharmaceuticals448
PifeltrodoravirineMerck & Co538
NarcannaloxoneAdapt Pharma077
Paxil CrparoxetineApotex Technologies044
Heparin SodiumheparinPfizer224
LamivudinealamivudineMylan Labs033
LamivudinealamivudineMylan Labs033
DTG/FTC/TAFtenofovirMylan Labs033
Paragard T 380copperCooperSurgical022
Metformin HydrochlorideametforminSun Pharma112
Fenofibrate (Micronized)fenofibrateCipla112
ZulressobrexanoloneSage Therap011
Zantac 75ranitidineSanofi US011
Hydrocodone Bitartrate And AcetaminophenaacetaminophenWes Pharma Inc011

As you can see from the table above, HCPs often mentioned the compound more than the brand name when discussing FDA approvals. This is consistent with what we see across product mentions in general by HCPs online.
Within the top five products discussed by HCPs, we can see that doctors were the most active. However, more role types spoke about Rybelsus® and Invokana®, including pharmacists, due to a wide range of HCPs engaging with patients around these products.

‘Game changing week’ and ‘majorly shake things up’ were some of the phrases used by HCPs to describe the approval of the first oral GLP-1 receptor agonist in management of type 2 diabetes, Rybelsus® (semaglutide). HCPs were overwhelmingly positive towards the new innovation by Novo Nordisk sharing this news over 100 times since its approval, which makes this the most mentioned product in this month’s online HCP conversation around FDA approvals.


The second most mentioned product with 94 mentions was Janssen’s Erleada® (apalutamide) which was approved for the treatment of metastatic prostate cancer. This expansion to the drug’s label was welcomed by HCPs with many sharing the TITAN trial data, showing patient benefit, that was used in the approval submission.


Even though Janssen had the most FDA approvals mentioned by HCPs (three), alongside Merck & Co and Mylan Labs, Novo Nordisk had the highest average number of mentions per approval over the month of September.

Manufacturer Approvals Mentions
Janssen 3 201
Novo Nordisk 1 118
Meck & Co (MSD) 3 68

We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge.

Read last month’s FDA Approval Tracker


View all articles >

Meet the Author

Nathan Cripps

Suggested next

02.11.2023 | Article

Product Launch Tracker: eHCPs had positive reaction to the approval of the Novavax COVID-19 vaccine.

Discover what new drug approvals HCPs are talking about

By Alexandra Maria Chatziioannidou

HCPs continue to unite in supporting patients and one another online

19.03.2020 | Article

HCPs continue to unite in supporting patients and one another online

HCPs continue to unite in supporting patients and one another online

By Laura McIntyre

View all articles >